Jeff Giullian, chief medical officer for DaVita, said at the time, adding, Based on the inclusion criteria for study participants, we believe there may be limited application of the FLOW study findings to the overall CKD patient population. He argued that the inclusion requirements necessary to partake in the FLOW trial, such as needing to be on a standard kidney disease treatment and have a certain amount of protein in the urine, were attributable to a narrow subset less than 10% of all current CKD patients
If that sentence sparked more questions than answers, know that Dr
If you decide to receive GLP-1 medications in Arlington, consult with our team to discuss which one suits your goals
This will be discussed with you during your initial consultation
Constipation , nausea, and bloating often result from this delayed gastric transit